. 2019 Oct 4;53(24):14649–14659. doi: 10.1021/acs.est.9b04255

Table 1. Reference Compounds Used During Method Development, Including Their Chemical Characteristics, Endocrine Disrupting Mechanism of Action (MoA), EC50 or IC50, Concentrations in Full-Term AF Reported in the Literature and Measured in This Study^38,40−54^a.

graphic file with name es9b04255_0005.jpg

Abbrev: AR, androgenic; ER, estrogenic; AhR, dioxin-like mode of action; PFASs, perfluorinated compounds; PBDEs, polybrominated diphenyl ethers; EC50, half maximal effective concentration; IC50, half maximal inhibitory concentrations; 4-OP, 4-octylphenol; PP, propylparaben; MnBP, mono-n-butyl phthalate; BPA, bisphenol A; BPS, bisphenol S; TCS, triclosan; MBP, 4-methyl-2,4-bis-(p-hydroxyphenyl)pent-1-ene; OH-PCB-61, 2,3,4,5-tetrachloro-4′-biphenylol; PFOS, perfluorooctanesulfonic acid; 6-OH-BDE-47, 6-hydroxy-2,2′,4,4′-tetrabromodiphenyl ether; 3-OH-BDE-153, 3-hydroxy-2,2′,4,4′,5,5′-hexabromodiphenyl ether; E2, 17β-estradiol; E1, estrone; E4, estetrol; FICZ, 6-formylindolo[3,2-b]carbazole; EC50 and IC50, values based on in vitro reporter gene assays; log P, partition coefficient based on octanol–water partitioning, values reported from PubChem or Chemspider database; symbols: () references from the literature; ^ mean concentrations of unconjugated compounds measured at full-term; * concentrations reported in midgestation; - not reported.

Table 1. Reference Compounds Used During Method Development, Including Their Chemical Characteristics, Endocrine Disrupting Mechanism of Action (MoA), EC50 or IC50, Concentrations in Full-Term AF Reported in the Literature and Measured in This Study38,40−54a.

Table 1. Reference Compounds Used During Method Development, Including Their Chemical Characteristics, Endocrine Disrupting Mechanism of Action (MoA), EC50 or IC50, Concentrations in Full-Term AF Reported in the Literature and Measured in This Study^38,40−54^a.